KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $20.7 million.

  • Rigel Pharmaceuticals' Change in Acquisitions & Divestments rose 24550.0% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.3 million, marking a year-over-year increase of 3948.65%. This contributed to the annual value of $39.7 million for FY2024, which is 468.19% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $20.7 million for Q3 2025, which was up 24550.0% from $15.8 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $30.8 million during Q4 2021, with a 5-year trough of $1.4 million in Q3 2021.
  • Its 5-year average for Change in Acquisitions & Divestments is $15.4 million, with a median of $15.6 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 9653.83% in 2021, then soared by 200271.62% in 2022.
  • Rigel Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $30.8 million in 2021, then plummeted by 31.39% to $21.2 million in 2022, then crashed by 71.65% to $6.0 million in 2023, then grew by 12.5% to $6.8 million in 2024, then surged by 207.11% to $20.7 million in 2025.
  • Its last three reported values are $20.7 million in Q3 2025, $15.8 million for Q2 2025, and $11.1 million during Q1 2025.